Chen C - Search Results

1

Integrating predictive biomarkers and classifiers into oncology clinical development programmes.

Beckman RA, Clark J, Chen C. Beckman RA, et al. Among authors: chen c. Nat Rev Drug Discov. 2011 Sep 30;10(10):735-48. doi: 10.1038/nrd3550. Nat Rev Drug Discov. 2011. PMID: 21959287 Review.

2

New evidence-based adaptive clinical trial methods for optimally integrating predictive biomarkers into oncology clinical development programs.

Beckman RA, Chen C. Beckman RA, et al. Among authors: chen c. Chin J Cancer. 2013 May;32(5):233-41. doi: 10.5732/cjc.012.10248. Epub 2013 Mar 15. Chin J Cancer. 2013. PMID: 23489587 Free PMC article.

3

Maximizing return on socioeconomic investment in phase II proof-of-concept trials.

Chen C, Beckman RA. Chen C, et al. Clin Cancer Res. 2014 Apr 1;20(7):1730-4. doi: 10.1158/1078-0432.CCR-13-2312. Epub 2014 Feb 13. Clin Cancer Res. 2014. PMID: 24526732

4

Translating predictive biomarkers within oncology clinical development programs.

Beckman RA, Chen C. Beckman RA, et al. Among authors: chen c. Biomark Med. 2015;9(9):851-62. doi: 10.2217/bmm.15.56. Epub 2015 Sep 2. Biomark Med. 2015. PMID: 26330133 Review.

5

Efficient, Adaptive Clinical Validation of Predictive Biomarkers in Cancer Therapeutic Development.

Beckman RA, Chen C. Beckman RA, et al. Among authors: chen c. Adv Exp Med Biol. 2015;867:81-90. doi: 10.1007/978-94-017-7215-0_6. Adv Exp Med Biol. 2015. PMID: 26530361 Review.

6

Adaptive Design for a Confirmatory Basket Trial in Multiple Tumor Types Based on a Putative Predictive Biomarker.

Beckman RA, Antonijevic Z, Kalamegham R, Chen C. Beckman RA, et al. Among authors: chen c. Clin Pharmacol Ther. 2016 Dec;100(6):617-625. doi: 10.1002/cpt.446. Epub 2016 Sep 19. Clin Pharmacol Ther. 2016. PMID: 27509351

7

A 2-in-1 adaptive phase 2/3 design for expedited oncology drug development.

Chen C, Anderson K, Mehrotra DV, Rubin EH, Tse A. Chen C, et al. Contemp Clin Trials. 2018 Jan;64:238-242. doi: 10.1016/j.cct.2017.09.006. Epub 2017 Sep 28. Contemp Clin Trials. 2018. PMID: 28966137

8

Optimal two-stage randomized multinomial designs for Phase II oncology trials.

Sun LZ, Chen C, Patel K. Sun LZ, et al. Among authors: chen c. J Biopharm Stat. 2009;19(3):485-93. doi: 10.1080/10543400902802417. J Biopharm Stat. 2009. PMID: 19384690

9

Evaluation of early efficacy endpoints for proof-of-concept trials.

Chen C, Sun L, Li CL. Chen C, et al. J Biopharm Stat. 2013 Mar 11;23(2):413-24. doi: 10.1080/10543406.2011.616969. J Biopharm Stat. 2013. PMID: 23437947

10

Independent action models and prediction of combination treatment effects for response rate, duration of response and tumor size change in oncology drug development.

Sun LZ, Wu C, Li X, Chen C, Schmidt EV. Sun LZ, et al. Among authors: chen c. Contemp Clin Trials. 2021 Jul;106:106434. doi: 10.1016/j.cct.2021.106434. Epub 2021 May 15. Contemp Clin Trials. 2021. PMID: 34004341

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results